Yangling Jitai Pharmaceutical Makes Debut at the 23rd China International Pharmaceutical Ingredients Expo, Driving Global Pharma Collaboration with Innovation

From June 24 to 26, 2025, the 23rd China International Pharmaceutical Intermediates & Ingredients Expo (CPHI China 2025) grandly opened at the Shanghai New International Expo Center. As a pivotal platform propelling China's pharmaceutical industry onto the global stage, this edition of the expo, with its massive scale of 230,000 square meters, attracted over 3,500 leading global enterprises and drew more than 100,000 professional attendees from around the world, establishing an international exchange and trade platform covering the entire pharmaceutical supply chain. Yangling Jitai Pharmaceutical Co., Ltd. (hereinafter referred to as "Jitai Pharmaceutical") showcased its core products and technological strengths, engaging with global pharmaceutical peers to explore new industry development opportunities and demonstrating the innovation vitality and international vision of domestic pharmaceutical enterprises.

As a leading event in the global pharmaceutical industry, CPHI China focuses on core areas such as pharmaceutical raw materials, natural extracts, biotechnology, pharmaceutical excipients, and formulations, deeply integrating the full industry chain resources from research and development to production, and from technology to trade. During the exhibition, not only did 159 high-quality overseas exhibitors from multiple countries such as India, Italy, Japan, the United States, and the United Kingdom make their debut, but more than 100 high-end industry forums were also carefully planned, covering popular topics such as policy and regulation interpretation, innovative technology research and development, market trend analysis, and international cooperation paths, providing a core hub for efficient docking and intelligent collision for global pharmaceutical companies. Jitai Pharmaceutical's participation in this exhibition is not only a comprehensive display of the company's core competitiveness, but also an important opportunity to deeply integrate into the global pharmaceutical ecosystem and draw on cutting-edge industry wisdom.

As one of the large-scale and innovative raw material manufacturing enterprises in Shaanxi Province, Jitai Pharmaceutical has always adhered to the core tenet of "scientific leadership, technological progress, and innovative development" since its establishment in 2017. It has deeply cultivated the entire chain of new drug research and development, production, and sales, with a total asset of 250 million yuan. It has built a modern production base of 45000 square meters, covering six functional areas including raw material workshops, formulation pilot workshops, pilot scale-up laboratories, and quality testing centers, forming a complete production system and strict quality control system. At this exhibition, the company focused on showcasing core active pharmaceutical ingredients such as oseltamivir phosphate and tadalafil. With product advantages and mature production processes, it has won high attention from exhibitors and partners at home and abroad.

At the exhibition site, Jitai Pharmaceutical's booth was crowded with people, with numerous buyers, distributors, and representatives from research institutions from around the world stopping to exchange ideas. The company's exhibition team conducted in-depth negotiations with visiting guests on core issues such as product application scenarios, technological innovation, quality standard control, and international cooperation models, relying on professional product interpretation and detailed technical Q&A. Multiple cooperation intentions were reached on site, and a number of high-quality potential partner resources were obtained. At the same time, the team actively visited various core exhibition areas of the exhibition, exchanged experiences with industry leaders and technological innovation pioneers, and gained in-depth understanding of the cutting-edge dynamics, policy guidance, and market demand of the global pharmaceutical industry, accumulating valuable experience for the company's subsequent product research and development upgrades and market layout optimization.

As a local enterprise deeply involved in the field of active pharmaceutical ingredients, Jitai Pharmaceutical has always taken "assisting the development of global pharmaceutical and health industry" as its mission. With strict quality control, continuous innovation capability, and a perfect service system, it has gradually become a high-quality active pharmaceutical ingredient supplier in China. This appearance at CPHI China 2025 is not only an important window for the company to showcase its core strength, but also a crucial step towards entering the international market.

As a local enterprise deeply involved in the field of active pharmaceutical ingredients, Jitai Pharmaceutical has always taken "assisting the development of global pharmaceutical and health industry" as its mission. With strict quality control, continuous innovation capability, and a perfect service system, it has gradually become a high-quality active pharmaceutical ingredient supplier in China. This appearance at CPHI China 2025 is not only an important window for the company to showcase its core strength, but also a crucial step towards entering the international market.